The acquisition will have a $600 million upfront payment and up to another $1.1 billion pending regulatory and commercial milestones, according to an Aug. 20 J&J news release.
V-Wave is a privately held company that targets heart failure with reduced ejection fraction, and its Ventura Interatrial Shunt addressed an unmet need for about 800,000 patients, the release said.
